JIA
MCID: JVN010
MIFTS: 66

Juvenile Rheumatoid Arthritis (JIA)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Juvenile Rheumatoid Arthritis

MalaCards integrated aliases for Juvenile Rheumatoid Arthritis:

Name: Juvenile Rheumatoid Arthritis 12 73 20 43 58 6 15 70 32
Juvenile Idiopathic Arthritis 12 20 43 58 36 15 17
Juvenile Chronic Arthritis 20 43 58
Monarticular Juvenile Rheumatoid Arthritis 12 70
Systemic Juvenile Rheumatoid Arthritis 12 43
Pauciarticular Juvenile Arthritis 12 32
Juvenile Chronic Polyarthritis 12 70
Arthritis, Juvenile Rheumatoid 20 43
Juvenile Arthritis 20 70
Still's Disease 12 73
Acute Polyarticular Juvenile Rheumatoid Arthritis 70
Pauciarticular Onset Juvenile Chronic Arthritis 12
Pauciarticular Juvenile Rheumatoid Arthritis 70
Rheumatoid Arthritis, Systemic Juvenile 70
Acute Juvenile Rheumatoid Arthritis 12
Arthritis Juvenile Rheumatoid 54
Stills Disease 54
Juvenile Ra 43
Jia 43
Jra 43

Characteristics:

Orphanet epidemiological data:

58
juvenile idiopathic arthritis
Prevalence: 1-9/100000 (Europe),1-9/100000 (France); Age of onset: Childhood;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:676
KEGG 36 H01672
ICD10 32 M08.0 M08.4
MESH via Orphanet 45 D001171
ICD10 via Orphanet 33 M08.0 M08.1 M08.2 more
UMLS via Orphanet 71 C0553662 C1444838 C3495559
Orphanet 58 ORPHA92
UMLS 70 C0157916 C0157917 C0157918 more

Summaries for Juvenile Rheumatoid Arthritis

MedlinePlus Genetics : 43 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints.Researchers have described seven types of juvenile idiopathic arthritis. The types are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history.Systemic juvenile idiopathic arthritis causes inflammation in one or more joints. A high daily fever that lasts at least 2 weeks either precedes or accompanies the arthritis. Individuals with systemic arthritis may also have a skin rash or enlargement of the lymph nodes (lymphadenopathy), liver (hepatomegaly), or spleen (splenomegaly).Oligoarticular juvenile idiopathic arthritis (also known as oligoarthritis) is marked by the occurrence of arthritis in four or fewer joints in the first 6 months of the disease. It is divided into two subtypes depending on the course of disease. If the arthritis is confined to four or fewer joints after 6 months, then the condition is classified as persistent oligoarthritis. If more than four joints are affected after 6 months, this condition is classified as extended oligoarthritis. Individuals with oligoarthritis are at increased risk of developing inflammation of the eye (uveitis).Rheumatoid factor positive polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor positive) causes inflammation in five or more joints within the first 6 months of the disease. Individuals with this condition also have a positive blood test for proteins called rheumatoid factors. This type of arthritis closely resembles rheumatoid arthritis as seen in adults.Rheumatoid factor negative polyarticular juvenile idiopathic arthritis (also known as polyarthritis, rheumatoid factor negative) is also characterized by arthritis in five or more joints within the first 6 months of the disease. Individuals with this type, however, test negative for rheumatoid factor in the blood.Psoriatic juvenile idiopathic arthritis involves arthritis that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a condition characterized by patches of red, irritated skin that are often covered by flaky white scales. Some affected individuals develop psoriasis before arthritis while others first develop arthritis. Other features of psoriatic arthritis include abnormalities of the fingers and nails or eye problems.Enthesitis-related juvenile idiopathic arthritis is characterized by tenderness where the bone meets a tendon, ligament, or other connective tissue. The most commonly affected places are the hips, knees, and feet. This tenderness, known as enthesitis, accompanies the joint inflammation of arthritis. Enthesitis-related arthritis may also involve inflammation in parts of the body other than the joints.The last type of juvenile idiopathic arthritis is called undifferentiated arthritis. This classification is given to affected individuals who do not fit into any of the above types or who fulfill the criteria for more than one type of juvenile idiopathic arthritis.

MalaCards based summary : Juvenile Rheumatoid Arthritis, also known as juvenile idiopathic arthritis, is related to systemic onset juvenile idiopathic arthritis and multicentric carpotarsal osteolysis syndrome, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Juvenile Rheumatoid Arthritis is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Leflunomide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include joint, eye and t cells, and related phenotypes are arthritis and fever

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

GARD : 20 Juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. When the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. Some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. Like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors. To be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. Diagnosis of the condition may be based on blood tests, X-rays, and ruling out other similar conditions. Treatment options may include medications and physical therapy.

KEGG : 36 Juvenile idiopathic arthritis (JIA) is one of the most common childhood rheumatic diseases. Clinically, it is defined as arthritis of unknown origin that starts before the age of 16, and persists for at least 6 weeks. Next to a certain genetic predisposition, environmental factors play a role leading to a chronic inflammatory response. JIA is not a single disorder but consists of a heterogeneous group of auto-immune inflammatory diseases. It has variable rates in course and activity of disease. Based on 6 months of clinical symptoms and global prognostic factors, the following clinical subtypes of JIA are recognized: systemic JIA, oligoarthritis, RF-negative polyarthritis, RF-positive polyarthritis, psoriatic JIA, enthesitis- related arthritis, and undifferentiated arthritis. Systemic JIA, also known as Still's disease, is a subtype with strong systemic clinical symptoms. Patients with systemic JIA have, in addition to arthritis, prominent symptoms of systemic inflammation such as spiking fever, rash, pericarditis, peritonitis, lymphadenopathy and organomegaly. A severe and often life-threatening complication occurring in 10-30% of patients with systemic JIA is macrophage activation syndrome. Polymorphisms in the IL6 and in the MIF gene have been found to be associated with susceptibility to the disorder. Based on the known relevance of IL6 in JIA pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA.

Wikipedia : 73 Juvenile idiopathic arthritis (JIA), is the most common, chronic rheumatic disease of childhood,... more...

Related Diseases for Juvenile Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Juvenile Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1254)
# Related Disease Score Top Affiliating Genes
1 systemic onset juvenile idiopathic arthritis 33.1 TNF IL6 HLA-DRB1
2 multicentric carpotarsal osteolysis syndrome 32.8 TNF IL6 BGLAP
3 adult-onset still's disease 32.2 TNF IL6 IL1RN IL1R1 CRP
4 iridocyclitis 31.8 TNF IL6 IL10 DEK CRP
5 uveitis 31.7 TNF LTA IL6 IL2RA IL1R1 IL10
6 exanthem 31.7 TNF IL6 IL10 CRP
7 macrophage activation syndrome 31.5 TNFRSF1B TNF CRP
8 juvenile arthritis 31.5 IL6 IL1R1 IL10 DEK CRP
9 arthropathy 31.5 TNF LTA IL6 CRP
10 pericarditis 31.5 TNF IL6 CRP
11 spondylitis 31.5 TNF LTA IL6 IL10 CRP
12 iritis 31.4 TNF IL6 IL10 CRP
13 vasculitis 31.3 TNF S100A9 IL6 CRP
14 synovitis 31.3 TNF IL6 IL1RN CRP
15 myocarditis 31.3 TNF IL6 IL10 HLA-DQB1
16 spondyloarthropathy 31.2 TNF LTA IL6 IL10
17 idiopathic anterior uveitis 31.2 TNF IL6
18 conjunctivitis 31.2 TNF IL6 IL10
19 disseminated intravascular coagulation 31.1 TNF IL6 IL10 CRP
20 lupus erythematosus 31.1 TNFRSF1B TNF IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
21 chickenpox 31.1 TNF IL6 IL10 CRP
22 bone resorption disease 31.1 TNF IL6 CRP BGLAP
23 lyme disease 31.1 TNF IL6 HLA-DRB1 HLA-DQB1 CRP
24 spondyloarthropathy 1 31.0 TNFRSF1B TNF IL6 IL1RN IL1R1 CRP
25 tenosynovitis 31.0 TNF IL6 CRP
26 bronchiolitis 31.0 TNF IL6 IL10 CRP
27 eye disease 31.0 TNF IL6 IL1RN IL1R1 IL10 CRP
28 rheumatic fever 30.9 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
29 juvenile ankylosing spondylitis 30.9 TNF IL1RN
30 polyarteritis nodosa 30.9 IL6 HLA-DRB1 CRP
31 thyroiditis 30.9 TNF IL6 IL10 HLA-DRB1 CRP
32 osteomyelitis 30.9 TNF IL6 IL1RN IL10 CRP
33 bronchiolitis obliterans 30.9 TNF IL6 IL10 CRP
34 childhood type dermatomyositis 30.9 TNF IL6 HLA-DQA1
35 pharyngitis 30.9 TNF IL6 HLA-DRB1 CRP
36 dermatitis 30.9 TNF IL6 IL2RB IL10
37 peritonitis 30.8 TNF IL6 IL10 CRP
38 demyelinating disease 30.8 TNF IL6 IL10 HLA-DRB1
39 periodontitis 30.8 TNF IL6 IL1RN IL10 CRP BGLAP
40 gastroenteritis 30.8 TNF IL6 IL1RN IL10 CRP
41 rubella 30.8 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
42 tendinitis 30.8 TNF IL6 CRP
43 herpes zoster 30.8 TNF IL10 HLA-DRB1
44 infective endocarditis 30.8 TNF IL6 CRP
45 systemic autoimmune disease 30.8 IL6 CRP
46 meningitis 30.8 TNF IL6 IL10 CRP
47 chorioretinitis 30.8 TNF IL6 IL10 CRP
48 cholangitis 30.8 TNF IL6 IL10 HLA-DRB1 CRP
49 castleman disease 30.8 IL6 IL10 CRP
50 meningoencephalitis 30.8 TNF IL6 IL10 CRP

Graphical network of the top 20 diseases related to Juvenile Rheumatoid Arthritis:



Diseases related to Juvenile Rheumatoid Arthritis

Symptoms & Phenotypes for Juvenile Rheumatoid Arthritis

Human phenotypes related to Juvenile Rheumatoid Arthritis:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001369
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
4 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
5 joint stiffness 58 31 frequent (33%) Frequent (79-30%) HP:0001387
6 malabsorption 58 31 frequent (33%) Frequent (79-30%) HP:0002024
7 generalized hyperkeratosis 58 31 frequent (33%) Frequent (79-30%) HP:0005595
8 abnormal fingernail morphology 58 31 frequent (33%) Frequent (79-30%) HP:0001231
9 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
10 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
11 uveitis 58 31 frequent (33%) Frequent (79-30%) HP:0000554
12 joint dislocation 58 31 frequent (33%) Frequent (79-30%) HP:0001373
13 skin rash 58 31 frequent (33%) Frequent (79-30%) HP:0000988
14 mediastinal lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0100721
15 cartilage destruction 58 31 frequent (33%) Frequent (79-30%) HP:0100773
16 abnormality of the sacroiliac joint 58 31 frequent (33%) Frequent (79-30%) HP:0100781
17 nail pits 58 31 frequent (33%) Frequent (79-30%) HP:0001803
18 psoriasiform dermatitis 58 31 frequent (33%) Frequent (79-30%) HP:0003765
19 abnormal pleura morphology 31 frequent (33%) HP:0002103
20 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
21 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
22 pericardial effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0001698
23 abnormality of the nail 58 Frequent (79-30%)
24 abnormality of the pleura 58 Frequent (79-30%)
25 thickened skin 58 Frequent (79-30%)
26 abnormal joint morphology 58 Frequent (79-30%)

UMLS symptoms related to Juvenile Rheumatoid Arthritis:


back pain; sciatica; muscle cramp

GenomeRNAi Phenotypes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.1 BGLAP HAPLN1 HLA-DPB1 HLA-DQB1 IL1RN SLC11A1

MGI Mouse Phenotypes related to Juvenile Rheumatoid Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 BGLAP HLA-DQA1 HLA-DQB1 IL10 IL1R1 IL1RN
2 immune system MP:0005387 10.24 BGLAP CRP HLA-DQA1 HLA-DQB1 IL10 IL1R1
3 endocrine/exocrine gland MP:0005379 10.17 BGLAP HLA-DQA1 HLA-DQB1 IL10 IL1R1 IL2RA
4 mortality/aging MP:0010768 10.1 HAPLN1 HLA-DQB1 IL10 IL1R1 IL1RN IL2RA
5 digestive/alimentary MP:0005381 10.06 HLA-DQB1 IL10 IL1R1 IL2RA IL6 SLC11A1
6 liver/biliary system MP:0005370 9.92 HLA-DQB1 IL10 IL1R1 IL2RB IL6 LTA
7 neoplasm MP:0002006 9.7 DEK IL10 IL1R1 IL6 SLC11A1 TNF
8 respiratory system MP:0005388 9.56 HLA-DQB1 IL10 IL1R1 IL2RA IL6 LTA
9 skeleton MP:0005390 9.32 BGLAP HAPLN1 IL10 IL1R1 IL1RN IL2RA

Drugs & Therapeutics for Juvenile Rheumatoid Arthritis

Drugs for Juvenile Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
9
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
10
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
11
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
12
Famotidine Approved Phase 4 76824-35-6 3325
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
16
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
17
Sodium citrate Approved, Investigational Phase 4 68-04-2
18
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
19
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
22 Neuroprotective Agents Phase 4
23 Methylprednisolone Acetate Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25 Protective Agents Phase 4
26 Cyclooxygenase 2 Inhibitors Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Liver Extracts Phase 4
29 Anti-Ulcer Agents Phase 4
30 Proton Pump Inhibitors Phase 4
31 Antacids Phase 4
32 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
33 Histamine H2 Antagonists Phase 4
34 Histamine Antagonists Phase 4
35
Histamine Phosphate Phase 4 51-74-1 65513
36 glucocorticoids Phase 4
37 Hormone Antagonists Phase 4
38 triamcinolone acetonide Phase 4
39 Triamcinolone diacetate Phase 4
40 Triamcinolone hexacetonide Phase 4
41 Pharmaceutical Solutions Phase 4
42 Hypnotics and Sedatives Phase 4
43 Adrenergic alpha-Agonists Phase 4
44 Neurotransmitter Agents Phase 4
45 Adrenergic Agents Phase 4
46 Adrenergic Agonists Phase 4
47 Citrate Phase 4
48 Tin Fluorides Phase 4
49 Antirheumatic Agents Phase 4
50 Analgesics, Non-Narcotic Phase 4

Interventional clinical trials:

(show top 50) (show all 214)
# Name Status NCT ID Phase Drugs
1 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
2 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
3 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
4 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
5 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
6 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
7 Genicular Nerve Block in Juvenile Idiopathic Arthritis Completed NCT04687930 Phase 4 genicular nerve block;intra-articular steroid injection
8 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
9 A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
10 A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
11 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
12 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
13 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Completed NCT00573651 Phase 4
14 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
15 Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial. Recruiting NCT04614311 Phase 4 Triamcinolone Hexacetonide 20 MG/ML
16 A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
17 Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial Recruiting NCT03816397 Phase 4
18 An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
19 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
20 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
21 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
22 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
23 A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
24 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
25 WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis Completed NCT01541917 Phase 3
26 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
27 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics Completed NCT01835470 Phase 3 Abatacept
28 A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
29 Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy Completed NCT02840175 Phase 3 etanercept;adalimumab;Abatacept;Tocilizumab
30 Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development Completed NCT00420251 Phase 3 Genotropin
31 An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA Completed NCT00144664 Phase 3 MRA(Tocilizumab)
32 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
33 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP Completed NCT00144612 Phase 3 MRA(Tocilizumab)
34 β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
35 A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
36 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
37 EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS Completed NCT02592434 Phase 3 CP-690,550 (tofacitinib)
38 Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977) Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
39 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
40 A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
41 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977) Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
42 An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02396212 Phase 3
43 An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever Completed NCT00891046 Phase 3 Canakinumab
44 A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Completed NCT00889863 Phase 3 canakinumab;placebo
45 Comparison of Iontophoresis of Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA®) Cream Versus Subcutaneous Injections of Lidocaine and EMLA® for Pain Relief in Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis: A Randomized Clinical Trial Completed NCT00465504 Phase 3
46 A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis Completed NCT03031782 Phase 3 AIN457
47 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
48 A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis Completed NCT00962741 Phase 3 Etanercept
49 AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1-3338-WW(B1801014) Completed NCT01421069 Phase 3 etanercept
50 Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo

Search NIH Clinical Center for Juvenile Rheumatoid Arthritis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Methotrexate
Methotrexate Sodium
Naproxen
Naproxen sodium
oxaprozin
solufenum
Sulfasalazine
tocilizumab
Tolmetin
Tolmetin Sodium

Genetic Tests for Juvenile Rheumatoid Arthritis

Anatomical Context for Juvenile Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Juvenile Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Juvenile Rheumatoid Arthritis:

40
Eye, T Cells, Bone, Spleen, Endothelial, Skin, Bone Marrow

Publications for Juvenile Rheumatoid Arthritis

Articles related to Juvenile Rheumatoid Arthritis:

(show top 50) (show all 8757)
# Title Authors PMID Year
1
Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. 61 54
19480843 2009
2
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. 61 54
18766426 2009
3
[Immunotherapy using IL-6 receptor as the target]. 61 54
18974624 2008
4
Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis. 61 54
20476957 2008
5
Refractory vertebral sarcoidosis responding to infliximab. 61 54
18766126 2008
6
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. 54 61
18716298 2008
7
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. 54 61
18332104 2008
8
The blockade of IL-6 signaling in rational drug design. 54 61
18473869 2008
9
Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. 61 54
18078633 2007
10
Tuberculous uveitis after treatment with etanercept. 54 61
17364199 2007
11
Construction and purification of the murine p75-murine IgG1 fusion protein. 61 54
17502870 2007
12
Etanercept: a review of its use in the management of rheumatoid arthritis. 54 61
17521223 2007
13
Problems encountered during anti-tumour necrosis factor therapy. 61 54
16979537 2006
14
Etanercept and demyelinating disease in a patient with psoriasis. 61 54
16384777 2006
15
Etanercept for psoriasis in the pediatric population: experience in nine patients. 54 61
16445417 2006
16
Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan--a preliminary report. 54 61
16341347 2005
17
Etanercept therapy in children with juvenile rheumatoid arthritis. 54 61
16341346 2005
18
Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 61 54
15801034 2005
19
Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs. 54 61
16378499 2005
20
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. 61 54
15468378 2004
21
HLA-DRB1 alleles and HLA-DRB1 shared epitopes are markers for juvenile rheumatoid arthritis subgroups in Colombian mestizos. 61 54
15120191 2004
22
Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. 54 61
13130482 2003
23
[Polymorphism of human HLA-DRB1 leukocyte antigen alleles and its association to juvenile rheumatoid arthritis in a sample of Colombian mestizo children]. 61 54
14582328 2003
24
Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. 54 61
12739045 2003
25
DEK binding to class II MHC Y-box sequences is gene- and allele-specific. 61 54
12823858 2003
26
Anti-TNF therapy for other inflammatory conditions. 61 54
12463467 2002
27
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. 61 54
12022325 2002
28
Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. 61 54
11083287 2000
29
Etanercept (Enbrel): update on therapeutic use. 61 54
11053088 2000
30
Stress induces increases in IL-6 production by leucocytes of patients with the chronic inflammatory disease juvenile rheumatoid arthritis: a putative role for alpha(1)-adrenergic receptors. 61 54
11024553 2000
31
Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. 61 54
10857800 2000
32
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. 54 61
10717011 2000
33
Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. 54 61
10616003 1999
34
Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. 61 54
10505742 1999
35
Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. 54 61
10025933 1999
36
Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). 61 54
10065630 1999
37
Autoantibodies to transcriptional regulation proteins DEK and ALY in a patient with systemic lupus erythematosus. 61 54
9952027 1999
38
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase. 61 54
10063803 1999
39
Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium. 54 61
9506577 1998
40
Cytokines in juvenile rheumatoid arthritis. 61 54
9309198 1997
41
Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis. 54 61
9150089 1997
42
HLA class II genes in Latvian patients with juvenile rheumatoid arthritis. 54 61
9027967 1997
43
Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. 54 61
8982123 1996
44
Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. 61 54
8912504 1996
45
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. 54 61
8843861 1996
46
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. 54 61
7473488 1995
47
Interaction between HLA-DR and HLA-DP, and between HLA and interleukin 1 alpha in juvenile rheumatoid arthritis indicates heterogeneity of pathogenic mechanisms of the disease. 54 61
7558921 1995
48
Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. 61 54
7699643 1994
49
Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate. 61 54
7944621 1994
50
Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. 54 61
8187333 1994

Variations for Juvenile Rheumatoid Arthritis

Expression for Juvenile Rheumatoid Arthritis

Search GEO for disease gene expression data for Juvenile Rheumatoid Arthritis.

Pathways for Juvenile Rheumatoid Arthritis

Pathways related to Juvenile Rheumatoid Arthritis according to KEGG:

36
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630

Pathways related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 TNFRSF1B TNF SLC11A1 S100A9 S100A8 LTA
2
Show member pathways
13.85 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
3
Show member pathways
13.71 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
4
Show member pathways
13.57 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
5
Show member pathways
13.42 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
6
Show member pathways
13.32 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
7
Show member pathways
13.24 TNF IL2RB IL2RA IL1R1 HLA-DRB1 HLA-DQB1
8
Show member pathways
13.18 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
9
Show member pathways
12.86 TNF IL6 IL2RB IL2RA HLA-DRB1 HLA-DQB1
10
Show member pathways
12.85 TNF LTA IL6 IL2RA IL10 HLA-DRB1
11 12.84 TNF LTA IL6 HLA-DRB1 HLA-DQB1 HLA-DQA1
12
Show member pathways
12.79 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
13
Show member pathways
12.73 TNFRSF1B TNF LTA IL6 IL1R1
14
Show member pathways
12.68 TNFRSF1B TNF IL2RA IL10 HLA-DRB1 HLA-DQB1
15 12.6 TNFRSF1B TNF IL2RB IL2RA IL1RN IL10
16
Show member pathways
12.43 IL6 IL2RB IL2RA IL10
17
Show member pathways
12.41 IL2RB IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
18
Show member pathways
12.39 TNFRSF1B TNF LTA IL6 IL2RB IL2RA
19
Show member pathways
12.39 TNF IL6 IL2RB IL2RA IL1R1 IL10
20
Show member pathways
12.37 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
21
Show member pathways
12.35 TNF S100A9 S100A8 IL6
22
Show member pathways
12.31 TNF IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
23
Show member pathways
12.29 TNF LTA IL6 IL2RA IL10
24
Show member pathways
12.24 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
25 12.23 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
26 12.21 TNF IL6 IL1RN IL10
27 12.17 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
28 12.15 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
29 12.05 TNF IL6 IL2RB IL2RA IL10
30 12.02 TNFRSF1B TNF IL6 IL10
31
Show member pathways
12.01 IL2RB IL2RA IL1R1 HLA-DRB1
32 12 TNFRSF1B TNF LTA IL6
33
Show member pathways
11.99 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
34 11.97 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
35 11.96 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
36 11.96 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
37 11.94 TNF IL6 IL1R1 IL10
38 11.92 TNF IL6 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
39
Show member pathways
11.84 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
40
Show member pathways
11.82 TNFRSF1B TNF LTA
41
Show member pathways
11.8 TNF LTA IL6 IL10
42 11.78 TNF IL6 IL10
43 11.78 TNF LTA IL2RB IL2RA IL1R1 IL10
44 11.77 TNF IL6 IL10
45 11.75 HLA-DRB1 HLA-DQB1 HLA-DQA1
46 11.75 TNF LTA IL6 IL2RA IL10
47
Show member pathways
11.72 LTA IL2RB IL2RA
48
Show member pathways
11.67 TNF IL2RB IL2RA
49 11.66 TNF LTA IL6 IL2RB IL2RA IL1R1
50 11.64 TNFRSF1B TNF LTA IL1R1

GO Terms for Juvenile Rheumatoid Arthritis

Cellular components related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.34 TNFRSF1B TNF SLC11A1 S100A9 S100A8 LTA
2 extracellular space GO:0005615 10.13 TNF S100A9 S100A8 LTA IL6 IL1RN
3 extracellular region GO:0005576 10.03 TNFRSF1B TNF S100A9 S100A8 LTA IL6
4 cell surface GO:0009986 10 TNF IL2RB IL2RA IL1R1 HLA-DRB1 HLA-DPB1
5 lysosome GO:0005764 9.95 SLC11A1 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
6 external side of plasma membrane GO:0009897 9.93 TNF IL2RB IL2RA IL1R1 HLA-DRB1
7 endosome membrane GO:0010008 9.91 SLC11A1 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
8 trans-Golgi network membrane GO:0032588 9.76 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
9 endocytic vesicle membrane GO:0030666 9.71 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
10 ER to Golgi transport vesicle membrane GO:0012507 9.67 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
11 transport vesicle membrane GO:0030658 9.62 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
12 interleukin-2 receptor complex GO:0005893 9.48 IL2RB IL2RA
13 clathrin-coated endocytic vesicle membrane GO:0030669 9.46 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
14 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
15 MHC class II protein complex GO:0042613 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1

Biological processes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.13 S100A9 S100A8 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
2 defense response to bacterium GO:0042742 9.97 TNF SLC11A1 S100A9 S100A8 IL10
3 T cell receptor signaling pathway GO:0050852 9.95 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
4 cellular response to lipopolysaccharide GO:0071222 9.94 TNFRSF1B TNF IL6 IL10
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF S100A9 S100A8 IL6
6 response to lipopolysaccharide GO:0032496 9.88 TNFRSF1B SLC11A1 S100A9 S100A8 LTA IL10
7 defense response to Gram-positive bacterium GO:0050830 9.87 TNF LTA IL6 CRP
8 positive regulation of T cell proliferation GO:0042102 9.86 IL6 IL2RA HLA-DPB1
9 antimicrobial humoral response GO:0019730 9.85 SLC11A1 S100A9 S100A8
10 humoral immune response GO:0006959 9.85 TNF LTA IL6
11 positive regulation of cytokine production GO:0001819 9.84 TNF SLC11A1 IL10
12 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.84 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
13 response to activity GO:0014823 9.82 IL6 IL10 BGLAP
14 regulation of inflammatory response GO:0050727 9.81 TNF S100A9 S100A8 IL1R1
15 positive regulation of phagocytosis GO:0050766 9.8 TNF SLC11A1 IL2RB
16 negative regulation of T cell proliferation GO:0042130 9.79 IL2RA IL10 HLA-DRB1
17 acute-phase response GO:0006953 9.78 IL6 IL1RN CRP
18 interferon-gamma-mediated signaling pathway GO:0060333 9.78 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
19 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL10
20 response to glucocorticoid GO:0051384 9.77 TNF IL6 IL1RN IL10 BGLAP
21 cytokine-mediated signaling pathway GO:0019221 9.76 TNFRSF1B TNF IL6 IL2RB IL2RA IL1RN
22 antigen processing and presentation GO:0019882 9.73 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
23 positive regulation of interferon-gamma production GO:0032729 9.72 TNF SLC11A1 LTA IL1R1 HLA-DPB1
24 regulation of neuroinflammatory response GO:0150077 9.7 TNFRSF1B IL6
25 interleukin-2-mediated signaling pathway GO:0038110 9.7 IL2RB IL2RA
26 inflammatory response to antigenic stimulus GO:0002437 9.7 IL2RA IL1RN HLA-DRB1
27 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.69 IL1RN IL10
28 chronic inflammatory response GO:0002544 9.69 S100A9 S100A8
29 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
30 autocrine signaling GO:0035425 9.68 S100A9 S100A8
31 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.68 IL6 IL1RN
32 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
33 positive regulation of glial cell proliferation GO:0060252 9.67 TNF LTA IL6
34 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.66 TNF LTA
35 negative regulation of cytokine production involved in immune response GO:0002719 9.66 TNF IL10
36 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.65 HLA-DRB1 HLA-DQB1
37 inflammatory response GO:0006954 9.65 TNFRSF1B TNF SLC11A1 S100A9 S100A8 IL6
38 chemokine production GO:0032602 9.64 S100A9 S100A8
39 peptidyl-cysteine S-nitrosylation GO:0018119 9.63 S100A9 S100A8
40 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
41 sequestering of zinc ion GO:0032119 9.61 S100A9 S100A8
42 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.6 HLA-DRB1 HLA-DQB1
43 neutrophil aggregation GO:0070488 9.56 S100A9 S100A8
44 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.56 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1
45 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.55 TNF LTA
46 immune response GO:0006955 9.44 TNFRSF1B TNF SLC11A1 LTA IL6 IL2RA

Molecular functions related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 TNF LTA IL6 IL1RN IL10
2 RAGE receptor binding GO:0050786 9.43 S100A9 S100A8
3 arachidonic acid binding GO:0050544 9.4 S100A9 S100A8
4 Toll-like receptor 4 binding GO:0035662 9.37 S100A9 S100A8
5 interleukin-2 binding GO:0019976 9.32 IL2RB IL2RA
6 interleukin-2 receptor activity GO:0004911 9.26 IL2RB IL2RA
7 MHC class II receptor activity GO:0032395 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1

Sources for Juvenile Rheumatoid Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....